We reviewed the outcome following use of recombinant activated factor VII (rVIIa) in patients with major bleeding post cardiothoracic surgery in our unit between January 2002 and July 2004. The unit consists of 16 cardiothoracic intensive care beds in a public metropolitan teaching hospital which serves as a referral centre for heart and lung transplant surgery. Patients with refractory bleeding following cardiothoracic surgical procedures who were treated with rVIIa were identified. A total of 12 episodes of rVIIa use were recorded in ten patients, including three episodes with ventricular assist devices, and 5 heart and/or lung transplants. The median dose used was 85 mg/kg. Chest tube drainage decreased in all patients following administration of rVIIa; median chest tube drainage decreased from 445 ml/h to 171 ml/h (P=0.03). Despite cessation of bleeding, mortality was high when rVIIa was used after more than 24 hours. In six episodes, despite early rVIIa use (within six hours), continued bleeding necessitated return to theatre, where a surgical source of bleeding was found. In this small retrospective study, rVIIa significantly reduced bleeding that was refractory to standard blood product transfusion. In this series of patients, those that did not respond to rVIIa early in the postoperative phase were found to have a surgical source of bleeding.
Re-exploration for bleeding following cardiac surgery is associated with worse outcomes, and occurs in 3 to 5% of cases 1 . Predictors of the need for reexploration include (among others) age, procedural complexity, cardiopulmonary bypass time and renal insufficiency. The need for re-exploration is associated with increased mortality, renal failure, sepsis, adult respiratory distress syndrome, and prolonged mechanical ventilation and ICU length of stay 1 . The cause of coagulopathy following cardiopulmonarybypass is multifactorial and related to a combination of dilution and consumption of coagulation factors, thrombocytopenia and platelet dysfunction, fibrinolysis, hypothermia and anticoagulant drugs. Despite anti-fibrinolytics, aggressive blood product use and warming of postoperative patients, some patients continue to bleed, necessitating reexploration.
Recombinant activated factor VII (rVIIa) was developed as a treatment for haemophilic patients with clotting factor inhibitors. It has subsequently been used to treat non-haemophilic patients who are suffering from life-threatening bleeding. There have been reports of success in bleeding precipitated by a range of causes in patients with previously normal coagulation pathways, such as during cardiopulmonary bypass [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and massive transfusions associated with trauma and surgery 12 , as well as temporary coagulation disorders induced by liver disease 13 , thrombocytopenia 14 , thrombocytopathia 15 and anticoagulants 16, 17 . Recently, rVIIa has been shown to reduce the progression in the size of intracerebral haemorrhage in non-coagulopathic patients 18 . Despite the potentially pro-thrombotic nature of the drug, relatively few thrombotic complications have been reported, which is thought to be related to the localized action of rVIIa at the site of vessel injury where tissue factor is expressed 19 .
We report our early experience of rVIIa use in the management of refractory bleeding in cardiothoracic patients during the peri-operative period at our centre.
mATeRIAlS AnD meThODS Following ethics committee approval, a retrospective chart audit was conducted. Patients who received rVIIa were identified via pharmacy records. Patient characteristics, procedural details, transfusion requirements, rVIIa dose, estimated blood loss and clinical outcomes, including thrombotic complications, were obtained. Due to the retrospective nature of the study, calculations of hourly blood losses were not available prior to ICU admission. To simplify the data analysis, average values of chest tube drainage were taken over a twelve-hour period before and after rVIIa administration; or between rVIIa dosing and the previous/next return to theatre if that time period was less than twelve hours. There was no formal protocol in terms of blood loss or blood product replacement guiding the administration of rVIIa. Any patient with severe or prolonged bleeding who was refractory to standard blood product replacement was considered for the treatment. An approval process was introduced involving discussion with a senior intensivist and our Director of haematology. The dose used was variable, depending on such factors as the severity of bleeding and the perceived risk of thrombotic complications. Chest tube drainage before and after rVIIa was compared using the Wilcoxon matched-pairs signed-rank test. Calculations were performed using STATA version 7.
ReSUlTS
There were twelve episodes of rVIIa use identified in ten patients between January 2002 and July 2004. A summary of the patients and the clinical events is described below. Two patients received two doses of rVIIa; both of these patients received the initial dose of rVIIa shortly after insertion of a ventricular assist device (VAD) and subsequently at the time of orthotopic heart transplantation. Operations performed, transfusion requirements prior to rVIIa and time from surgery to administration of rVIIa are shown in Table 1 . Patient temperature and ph at the time of rVIIa, the dose of rVIIa used and the outcome of rVIIa use in terms of effect on prothrombin time (PT), thrombotic events post administration, and survival are shown in Table 2 . Drain losses prior to and after rVIIa, and the number of times the patient returned to theatre prior to rVIIa are shown in Table  3 . There were eight episodes of rVIIa use where chest tube drainage was available for comparison pre and post rVIIa. The median chest tube drainage in these patients was significantly reduced from 445 ml/h to 171 ml/h (P=0.03). Four of these patients required further surgery, but a surgical source of bleeding was found in all cases. In these patients, median chest tube drainage decreased from 845 ml/h to 534 ml/h (P=0.06)
Patient 1
A 62-year-old man with a post-pneumonic loculated empyema underwent video-assisted thoracotomy with drainage and talc pleurodesis. eight days after his initial procedure the patient underwent decortication via a right thoracotomy. Postoperatively, despite blood product transfusion he continued to bleed and was taken back to the operating theatre where a haemothorax was evacuated and the chest was packed. At re-exploration there was evidence of coagulopathic bleeding, with diffuse microvascular bleeding and no specific bleeding points. Chest tube drainage continued at 246 ml/h over the next 12 hours despite normal coagulation parameters. Two doses of rVIIa 90 mg/kg were administered in addition to ongoing blood product transfusion and desmopressin (DDAVP). The patient was again returned to theatre after the first dose and the packs were removed. Again, no specific bleeding site was identified. Following return from theatre, blood loss decreased to 58 ml/h over the next 12 hours. Subsequent problems included acute lung injury, pneumonia and a bronchopleural fistula. he died of multiple-organ failure on postoperative day 11.
Patient 2
A 62-year-old male undergoing elective coronary artery bypass grafting (CABg) for critical coronary artery disease suffered a cardiac arrest following induction of anaesthesia. This required prolonged cardiorespiratory resuscitation and emergency cardiopulmonary bypass. Four coronary artery bypass grafts were performed. Upon admission to ICU the patient required high-dose inotropes, was anuric and had an ischaemic liver injury. Despite ongoing blood product transfusion, chest tube drainage was 5000 ml for two hours and he returned to theatre where no specific bleeding points were found. Upon return to ICU drainage continued at 340 ml/h over the subsequent 13.5 hours. he was returned to theatre because of ongoing bleeding and pericardial tamponade. At the third operation no bleeding source was identified and the chest was left open. Drainage continued at 153 ml/h over the next eight hours at which time 90 mg/kg rVIIa was administered. Drainage decreased to 76ml/h over the subsequent 12 hours. The patient died three days after the initial procedure from progressive cardiogenic shock and multipleorgan failure.
Patient 3
A 42-year-old male was admitted to ICU 25 days after a single lung transplant with native lung pneumonia, thoracotomy wound dehiscence and pancytopenia related to his immunosuppresive therapy. The following day the thoracotomy wound was explored, clot evacuated and the wound closed. Despite ongoing blood product transfusion, chest tube drainage continued at 125 ml/h over the next 24 hours. Two doses of 90 mg/kg rVIIa were given two hours apart and drain output decreased to 50 ml/h over the next 12 hours.
Patient 4
A 54-year-old male with an acute type A aortic dissection and pericardial tamponade underwent repair with aortic root replacement involving 22 minutes of hypothermic circulatory arrest. In the ICU, chest tube drainage over the next two hours was 600 ml/h. At re-operation a bleed at the proximal suture line led to cardiac arrest. Cardiopulmonary bypass was re-commenced and following repair it was apparent that a large anterior myocardial infarct had been sustained. An Abiomed left ventricular assist device (VAD) (Abiomed, mA, U.S.A.) was placed and he was removed from bypass on high-dose inotropes and transferred to the ICU. Bleeding continued from drains at over 1000 ml/h and the patient was given 80 mg/kg rVIIa prior to return to theatre. The patient died intra-operatively, and therefore no assessment of the effect of rVIIa could be made.
Patient 5 Episode a
A 56-year-old male with an ischaemic cardiomyopathy, previous coronary artery bypass surgery and deteriorating renal and liver function had a VAD inserted as a bridge to transplant. Cardiopulmonary bypass time was 389 minutes. Initially a Thoratec™ lVAD was placed (Thoratec Corporation, Pleasanton, CA, U.S.A.), but subsequently right ventricular dysfunction led to reinstitution of bypass and placement of a right VAD. The procedure was complicated by ongoing bleeding and massive transfusion. Prior to ICU admission, chest tube drainage was in excess of 1000 ml/h despite near normal coagulation parameters. On arrival in ICU a dose of 50 mg/kg rVIIa was given. Although the PT normalized, chest tube drainage continued at 725 ml/h over the next six hours. Drainage diminished over the subsequent three-six hour periods to 300, 53 and 43 ml/h respectively. Twenty-six hours after ICU admission, he was taken back to theatre where a bleeding site at an anastomotic site was repaired.
Patient 5 Episode b
Twenty-two days after the VAD procedure, the patient had an orthotopic heart transplant. After prolonged attempts at haemostasis the mediastinum was packed and the patient transferred to the ICU. Prior to transfer he was given 50 mg/kg rVIIa.
Drainage over the next 4.5 hours was 590 ml/h after which time he was returned to theatre where active bleeding was found at the aortic suture line. he made a good recovery but on the seventh postoperative day he was noted to have a swollen left arm and a Doppler ultrasound confirmed left axillary and jugular vein thrombosis.
Patient 6
A 33-year-old male underwent bilateral sequential lung transplant for chronic fibrotic lung disease secondary to a previous staphylococcal pneumonia. Postoperatively he was hypotensive despite inotropes and pressors with ongoing chest tube drainage of 690 ml/h over the first four hours. he received blood products, DDAVP, prothrombin complex concentrate, and aminocaproic acid. he was given 65 mg/kg rVIIa with no significant change in chest tube drainage and returned to theatre where no bleeding source was identified. Because of ongoing bleeding, he was again returned to theatre where a bleeding bronchial artery was identified and oversewn. Chest tube drainage slowly decreased and averaged 110 ml/h over the next 12 hours. Subsequently ventilatory support was withdrawn on day 11 and he was discharged from ICU on day 17.
Patient 7 Episode a
A 19-year-old male was transferred to our unit with cardiogenic shock, renal failure and ischaemic liver injury, secondary to a dilated cardiomyopathy with evidence of recent mycoplasma infection. An Abiomed™ BiVAD (Abiomed, mA, U.S.A.) was implanted. Intra-operatively, due to coagulopathic bleeding, a dose of rVIIa of 20 mg/kg was administered. Drainage postoperatively was 171 ml/h over the first 12 hours and decreased thereafter. On the third postoperative day a swollen left arm was noted and Doppler ultrasound demonstrated a cephalic vein thrombosis and a nonocclusive left internal jugular thrombosis. Anticoagulation with heparin was commenced. On the fourth postoperative day a small area of clot was noted in one of the Abiomed™ chambers, which extended over the subsequent three days. The upper limb swelling resolved, hepatic and renal failure improved, and on the sixth postoperative day the Abiomed™ system was replaced by a Thoratec™ BiVAD.
Patient 7 Episode b
Thirty-eight days after the BiVAD implantation and one week after recovery of renal function, the patient received a heart transplant. Immediately prior to transplantation he was on aspirin and warfarin with an international normalized prothrombin ratio of 2.0. Despite extensive use of blood products, intra-operative haemostasis was difficult. At the end of the procedure a dose of 100 mg/kg rVIIa was given. Drainage during the first 12 hours postoperatively was 30 ml/h.
Patient 8
A 46-year-old female with a history of eisenmenger's syndrome secondary to a ventricular septal defect underwent a heart and lung transplant. She had undergone a previous thoracotomy and a failed attempt at closure of a patent ductus arteriosus at another centre and was taking warfarin for a previous pulmonary embolism. At operation, bleeding from the patent ductus arteriosus was uncontrollable, leading to replacement of the ascending aorta and aortic arch in addition to the heart-lung transplant. hypothermic circulatory arrest time was 59 minutes. The chest could not be closed due to poor right ventricular function. In the first two hours postoperatively, chest drainage was 365 ml/h and two doses of 50 mg/kg rVIIa were given two hours apart. Drainage reduced to 100 ml/h over the next 10 hours, at which point the patient was taken back to theatre where a bleeding source was found at the right atrial suture line. An upper limb venous thrombosis was diagnosed on day 18.
Patient 9
A 55-year-old male with a history of chronic interstitial pneumonia underwent bilateral sequential lung transplant with a CPB time of 213 minutes. Chest tube drainage in the first postoperative hour was 1550 ml. rVIIa100 mg/kg was administered. Drainage continued at 555ml/h over the subsequent two hours. On return to theatre a bleeding bronchial artery was identified and secured. Drainage over the subsequent 12 hours was 51 ml/h. he was extubated on the second postoperative day and made a good recovery with no thrombotic events.
Patient 10
A 63-year-old man presented for an emergency coronary angiogram to investigate ongoing chest pain after a non ST segment elevation myocardial infarct. During angiography the left anterior descending coronary artery became occluded. An intra-aortic balloon pump was inserted and the patient was transferred for emergency coronary artery bypass. The patient had received enoxaparin 1 mg/kg and tirofiban 0.4 mg prior to angiography. Postoperatively chest tube drainage was 495 ml/h over the first four hours and the patient returned to theatre for drainage of pericardial tamponade. no bleeding source was identified but bleeding continued in the ICU at 348 ml/h over the next nine hours despite a normal prothrombin time. rVIIa 30 mg/kg was administered, after which drainage was reduced to 174 ml/h. Two and a half hours later the patient returned to theatre where clotted blood was evacuated and minimal ooze was reported. Drainage over the subsequent 12 hours was 46 ml/h. he was discharged from the ICU on day 7.
DISCUSSIOn
Several papers have reported dramatic effects after using rVIIa in cardiothoracic patients with postoperative bleeding [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . however, due to the lack of randomized controlled trials in this area, further evidence on the efficacy and safety of rVIIa is required, even if it is anecdotal. We report the use of rVIIa in a group of cardiothoracic patients including those requiring ventricular assist devices and following heart and lung transplantation.
In previous reports, the doses of rVIIa that have been used have varied widely, as has the timing of administration of rVIIa. Two small studies have shown significantly decreased peri-operative blood loss in patients treated with rVIIa prophylactically, in liver transplant 20 and open prostatectomy 21 patients. A third trial failed to show reduced transfusion requirement in non-cirrhotic patients undergoing partial hepatectomy 22 . A recently published trial randomized 48 patients undergoing semi-elective repair of pelvic or acetabular fractures to placebo or 90 mg/kg rVIIa-no reduction in peri-operative blood loss or transfusion requirement was demonstrated 23 . Off label use of rVIIa is usually reserved until 'conventional treatment' has failed, although there is no consensus as to what stage conventional treatment of a severe peri-operative coagulopathy has failed 24 .
The use of rVIIa in our unit has evolved over time. The initial two patients were each taken back to theatre twice, over a period of over 24 hours, during which they received massive transfusions. The first was given rVIIa just before the second re-operation and the second patient was given rVIIa 13.5 hours after the second re-operation had showed no surgical cause for bleeding. Both patients responded to rVIIa but died of multiple organ failure in the ensuing days. The third patient had a persisting coagulopathy and bleeding following thoracotomy, which responded to rVIIa after 26 hours. The fourth patient died of an event unrelated to, but soon after administration of rVIIa and no assessment of its effect could be made. In the next seven episodes of rVIIa use the drug was administered early, prior to re-operation in patients undergoing either transplant or VAD surgery. In all of these cases the patients had received significant replacement of blood products and continued to ooze intra-operatively or bleed postoperatively. Although five of these seven patients went on to require further surgery where a surgical component to their bleeding was found, it is noted that administration of rVIIa led to a drop in chest tube drainage for the four patients with pre and post rVIIa values for comparison. early administration of rVIIa in this group of patients appeared to correct the coagulation disorder, which assisted in identifying patients who had a surgical source of bleeding. All seven of these patients survived to hospital discharge. earlier use of rVIIa has been advocated by Clark et al who retrospectively examined the 'last ditch' use of rVIIa in ten patients with intractable bleeding 25 . Although bleeding was reduced in six patients, the seven day mortality rate was 70%, with late mortality being due to multipleorgan failure. It is possible that rVIIa may have been more efficacious in these cases if it had been administered earlier, prior to the development of hypothermia, hypoperfusion, acidosis and early organ dysfunction. In our series, rVIIa was given to two patients intra-operatively, at which time they could be seen clinically to have coagulopathic bleeding despite blood product administration. It has been reported that rVIIa given at this time may aid in clearing the surgical field and allow the surgeon to ensure adequate haemostasis during the primary procedure 26 . Significant postoperative bleeding usually mandates a return to theatre for re-exploration. In patients 5a, 5b, 6 and 9, rVIIa was given at 0, 0, 4 and 1 hours postoperatively. All four of these patients went on to have a surgical component to their bleeding discovered at subsequent operation.
The site of action of rVIIa is reported as being limited to the site of injury, leading to few reported thrombotic adverse events. Between 1996 and Oct 2001 there were 17 cases of adverse thrombotic events reported in more than 480,000 standard doses of rVIIa in haemophilic patients 27 . This contrasts with data from the novoSeven™ extendeduse data collection system in which O'Connell et al examined data of 40 patients treated with rVIIa for massive haemorrhage retrospectively, and found three adverse thrombotic events 28 . In our series, there were four thrombotic adverse events. Of most concern were the clots related to ventricular assist devices. lower doses of rVIIa were used in the VAD patients, reflecting the concerns regarding possible disastrous thrombotic adverse consequences, and the limited published experience in this clinical scenario. Theoretically, rVIIa should not induce clot formation on the extracorporeal circuit surface as tissue factor is not expressed here, but instead the anastomotic sites would provide the substrate for clot formation. The other two adverse thrombotic events that occurred were at the site of intravascular catheters, although one was 18 days post rVIIa administration. All patients were anticoagulated as soon as it was deemed safe and no long-term clinically apparent adverse sequelae occurred.
Successful use of rVIIa has previously been reported in VAD patients without sequelae 6, 7 . Catastrophic extracorporeal membrane oxegynator circuit thrombosis has been reported when rVIIa was used in combination with prothrombin complex concentrate 29 . In a recent study, the use of rVIIa to treat patients with intracerebral bleeds and normal clotting was also associated with increased thrombotic events 18 .
As with the timing, the optimal dosage of rVIIa administration has yet to be determined. The most common dosage often has been extrapolated from the 90 mg/kg doses used in haemophiliac patients. In our series of patients, operated on by a number of surgeons and treated by a number of intensivists, the median dose was 85 mg/kg, and all but the lowest dose used led to correction of the PT. The smallest (20 mg/kg) dose was given in episode 7a post VAD implantation. The patient was suffering an ischaemic hepatopathy and although the PT remained elevated at 19 seconds post rVIIa the bleeding did decrease and no re-operation was required. O'Connell et al found no correlation between dose and treatment success or failure in the forty patients included in the extended-use data collection system, in which doses used ranged from 15 to 180 mg/kg 28 . hypothermia impairs coagulation, and it has been shown that lower core temperatures postoperatively in cardiac surgical patients are associated with increased chest tube drainage 30 . It has been shown in vitro that the tissue factor independent action of rVIIa is not reduced by hypothermia at 24°C. however, a drop in ph from 7.4 to 7.0 reduces the action of rVIIa and the activity of the rVIIa/TF and prothrombinase complex significantly 31 . Five of the patients in our series were given rVIIa when their ph was 7.2 or less. All of these patients had a prothrombin time of between 10 and 12 seconds following rVIIa administration.
In summary, although no firm conclusions can be made on the basis of a retrospective chart review, we found that rVIIa appeared to be effective at reversing coagulopathies resistant to standard blood product transfusion in our complicated cardiothoracic patients, and in reducing blood loss in the majority of these cases. Our findings add to previous anecdotal evidence that smaller doses than those used in haemophilic patients may be effective in some patients. In our series of patients, continued bleeding after administration of rVIIa early in the postoperative phase was associated with a surgical source of bleeding. Several of our patients developed thrombotic complications, but it was not possible to determine whether these were related to the use of rVIIa. Further randomized controlled trials addressing the issues of safety, dosage and timing of rVIIa are required for the optimal use of this therapy in the management of the bleeding cardiothoracic patient. Until such evidence is available rVIIa should be used only after optimal blood product replacement therapy and exclusion of a surgical cause for bleeding.
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